Literature DB >> 17991736

CIITA mediates interferon-gamma repression of collagen transcription through phosphorylation-dependent interactions with co-repressor molecules.

Yong Xu1, Jonathan A Harton, Barbara D Smith.   

Abstract

Previously, we have demonstrated that major histocompatibility class II trans-activator (CIITA) is crucial in mediating interferon-gamma (IFN-gamma)-induced repression of collagen type I gene transcription. Here we report that CIITA represses collagen transcription through a phosphorylation-dependent interaction between its proline/serine/threonine domain and co-repressor molecules such as histone deacetylase (HDAC2) and Sin3B. Mutation of a serine (S373A) in CIITA, within a glycogen synthase kinase 3 (GSK3) consensus site, decreases repression of collagen transcription by blocking interaction with Sin3B. In vitro phosphorylation of CIITA by GSK3 relies on a casein kinase I site three amino acids C-terminal to the GSK3 site in CIITA. Both GSK3 and casein kinase I inhibitors alleviate collagen repression and disrupt IFN-gamma-mediated recruitment of Sin3B and HDAC2 to the collagen start site. Therefore, we have identified the region within CIITA responsible for mediating IFN-gamma-induced inhibition of collagen synthesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991736     DOI: 10.1074/jbc.M707180200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.

Authors:  Kavita Purnanda Bhat; Agnieszka Dorota Truax; Susanna Fletcher Greer
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  The effect of class II transactivator mutations on bleomycin-induced lung inflammation and fibrosis.

Authors:  Yong Xu; Larry Luchsinger; Edgar C Lucey; Barbara D Smith
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-12       Impact factor: 6.914

3.  A genetic screen in macrophages identifies new regulators of IFNγ-inducible MHCII that contribute to T cell activation.

Authors:  Michael C Kiritsy; Laurisa M Ankley; Justin Trombley; Gabrielle P Huizinga; Audrey E Lord; Pontus Orning; Roland Elling; Katherine A Fitzgerald; Andrew J Olive
Journal:  Elife       Date:  2021-11-08       Impact factor: 8.140

Review 4.  Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).

Authors:  Eléonore Beurel; Suzanne M Michalek; Richard S Jope
Journal:  Trends Immunol       Date:  2009-10-14       Impact factor: 16.687

5.  Major histocompatibility class II transactivator expression in smooth muscle cells from A2b adenosine receptor knock-out mice: cross-talk between the adenosine and interferon-gamma signaling.

Authors:  Yong Xu; Katya Ravid; Barbara D Smith
Journal:  J Biol Chem       Date:  2008-03-21       Impact factor: 5.157

6.  Stable protein, unstable plaque?

Authors:  Nicholas E S Sibinga
Journal:  J Mol Cell Cardiol       Date:  2008-12-03       Impact factor: 5.000

Review 7.  Sin3: master scaffold and transcriptional corepressor.

Authors:  Adrienne Grzenda; Gwen Lomberk; Jin-San Zhang; Raul Urrutia
Journal:  Biochim Biophys Acta       Date:  2009-06-06

8.  Constitutive IFNα/β signaling maintains expression of signaling intermediaries for efficient cytokine responses.

Authors:  Nicole L Messina; Christopher J P Clarke; Ricky W Johnstone
Journal:  JAKSTAT       Date:  2016-05-18

Review 9.  Regulating the activity of class II transactivator by posttranslational modifications: exploring the possibilities.

Authors:  Xiaoyan Wu; Xiaocen Kong; Larry Luchsinger; Barbara D Smith; Yong Xu
Journal:  Mol Cell Biol       Date:  2009-08-31       Impact factor: 4.272

10.  Tumor suppressor protein p53 recruits human Sin3B/HDAC1 complex for down-regulation of its target promoters in response to genotoxic stress.

Authors:  Nidhi Bansal; Rama Kadamb; Shilpi Mittal; Leena Vig; Raisha Sharma; Bilikere S Dwarakanath; Daman Saluja
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.